CDXS
Price
$2.77
Change
+$0.14 (+5.32%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
229.05M
50 days until earnings call
TECH
Price
$58.47
Change
-$4.43 (-7.04%)
Updated
Mar 11 closing price
Capitalization
9.24B
49 days until earnings call
Ad is loading...

CDXS vs TECH

Header iconCDXS vs TECH Comparison
Open Charts CDXS vs TECHBanner chart's image
Codexis
Price$2.77
Change+$0.14 (+5.32%)
Volume$9.44K
Capitalization229.05M
Bio-Techne
Price$58.47
Change-$4.43 (-7.04%)
Volume$3.07M
Capitalization9.24B
CDXS vs TECH Comparison Chart
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. TECH commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Buy and TECH is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (CDXS: $2.64 vs. TECH: $58.44)
Brand notoriety: CDXS and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 184% vs. TECH: 198%
Market capitalization -- CDXS: $229.05M vs. TECH: $9.24B
CDXS [@Biotechnology] is valued at $229.05M. TECH’s [@Biotechnology] market capitalization is $9.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 2 green, 3 red.
According to our system of comparison, TECH is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while TECH’s TA Score has 5 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 4 bearish.
  • TECH’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, TECH is a better buy in the short-term than CDXS.

Price Growth

CDXS (@Biotechnology) experienced а -3.47% price change this week, while TECH (@Biotechnology) price change was -2.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.64%. For the same industry, the average monthly price growth was -8.11%, and the average quarterly price growth was -7.39%.

Reported Earning Dates

CDXS is expected to report earnings on May 01, 2025.

TECH is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (+0.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($9.24B) has a higher market cap than CDXS($229M). TECH YTD gains are higher at: -18.770 vs. CDXS (-44.654). TECH has higher annual earnings (EBITDA): 307M vs. CDXS (-30.09M). CDXS has less debt than TECH: CDXS (41.8M) vs TECH (399M). TECH has higher revenues than CDXS: TECH (1.2B) vs CDXS (64.4M).
CDXSTECHCDXS / TECH
Capitalization229M9.24B2%
EBITDA-30.09M307M-10%
Gain YTD-44.654-18.770238%
P/E RatioN/A59.63-
Revenue64.4M1.2B5%
Total Cash90.3MN/A-
Total Debt41.8M399M10%
FUNDAMENTALS RATINGS
CDXS vs TECH: Fundamental Ratings
CDXS
TECH
OUTLOOK RATING
1..100
5553
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
9574
PRICE GROWTH RATING
1..100
9863
P/E GROWTH RATING
1..100
10028
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for CDXS (46) in the Chemicals Specialty industry. This means that TECH’s stock grew somewhat faster than CDXS’s over the last 12 months.

TECH's Profit vs Risk Rating (79) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that TECH’s stock grew similarly to CDXS’s over the last 12 months.

TECH's SMR Rating (74) in the Biotechnology industry is in the same range as CDXS (95) in the Chemicals Specialty industry. This means that TECH’s stock grew similarly to CDXS’s over the last 12 months.

TECH's Price Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for CDXS (98) in the Chemicals Specialty industry. This means that TECH’s stock grew somewhat faster than CDXS’s over the last 12 months.

TECH's P/E Growth Rating (28) in the Biotechnology industry is significantly better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that TECH’s stock grew significantly faster than CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSTECH
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 22 days ago
85%
Bullish Trend 5 days ago
72%
Declines
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 8 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
72%
View a ticker or compare two or three
Ad is loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGFYX72.98N/A
N/A
Columbia Large Cap Growth Inst3
SDMGX17.40N/A
N/A
Sit Developing Markets Growth
TGVFX47.29N/A
N/A
Touchstone Growth Opportunities A
JHEIX19.35N/A
N/A
JHancock Equity Income A
TBWCX18.46N/A
N/A
Thornburg Better World International C

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
-6.38%
DNLI - CDXS
46%
Loosely correlated
-10.43%
AXON - CDXS
43%
Loosely correlated
-2.08%
ABCL - CDXS
43%
Loosely correlated
-5.36%
AVIR - CDXS
41%
Loosely correlated
-2.01%
TECH - CDXS
40%
Loosely correlated
-2.28%
More